Hypogonadism causes bone loss and increased bone metastases in a model of mixed osteolytic/osteoblastic metastases: Prevention by zoledronic acid

被引：0
|
作者：
Padalecki, SS [1 ]
Carreon, M [1 ]
Grubbs, B [1 ]
Guise, TA [1 ]
机构：
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1589 / 1590
页数：2
相关论文
共 50 条
  • [41] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    BREAST, 2005, 14 : S45 - S46
  • [42] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    Rosen, L.
    Gordon, D.
    Chen, Y. M.
    CANCER TREATMENT REVIEWS, 2006, 32 : S43 - S43
  • [43] ZOLEDRONIC ACID ROLE IN SRES PREVENTION: AN ADVANTAGE FOR ALL PATIENTS WITH ADVANCED NSCLC AND BONE METASTASES?
    Del Signore, E.
    De Marinis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S78 - S78
  • [44] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    BREAST, 2005, 14 : S44 - S44
  • [45] Zoledronic acid reduces bone resorption markers in patients with lytic and blastic bone metastases
    Saad, F
    Gleason, D
    Rosen, L
    Gordon, D
    BONE, 2002, 30 (03) : 53S - 53S
  • [46] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Pectasides, D
    Nikolaou, M
    Farmakis, D
    Kanakis, I
    Gaglia, A
    Kountourakis, P
    Karamanos, NK
    Economopoulos, T
    Raptis, SA
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1457 - 1463
  • [47] Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases
    Steller, Daniel
    Simon, Ronja
    Von Bialy, Robert
    Pries, Ralph
    Hakim, Samer G.
    ANTICANCER RESEARCH, 2021, 41 (08) : 3917 - 3923
  • [48] Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone Metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline
    Mystakidou, K
    Katsouda, E
    Parpa, E
    Kelekis, A
    Galanos, A
    Vlahos, L
    MEDICAL ONCOLOGY, 2005, 22 (02) : 195 - 201
  • [49] Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline
    Kyriaki Mystakidou
    Emmanuela Katsouda
    Efi Parpa
    Alexis Kelekis
    Antonis Galanos
    Lambros Vlahos
    Medical Oncology, 2005, 22 : 195 - 201
  • [50] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Tas, Faruk
    Duranyildiz, Derya
    Oguz, Hilal
    Camlica, Hakan
    Yasasever, Vildan
    Topuz, Erkan
    MEDICAL ONCOLOGY, 2008, 25 (03) : 346 - 349
12345